300 related articles for article (PubMed ID: 31562896)
1. Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis.
Guo C; Wu K; Liang X; Liang Y; Li R
Pharmacol Res; 2019 Oct; 148():104455. PubMed ID: 31562896
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine A for induction of remission in severe ulcerative colitis.
Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K
Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids.
Narula N; Marshall JK; Colombel JF; Leontiadis GI; Williams JG; Muqtadir Z; Reinisch W
Am J Gastroenterol; 2016 Apr; 111(4):477-91. PubMed ID: 26856754
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis.
Zhao HN; Jiang M; Sun MJ; Dai C
Saudi J Gastroenterol; 2021; 27(4):191-200. PubMed ID: 34380865
[TBL] [Abstract][Full Text] [Related]
6. Systematic review: Infliximab therapy in ulcerative colitis.
Gisbert JP; González-Lama Y; Maté J
Aliment Pharmacol Ther; 2007 Jan; 25(1):19-37. PubMed ID: 17229218
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis.
Lv R; Qiao W; Wu Z; Wang Y; Dai S; Liu Q; Zheng X
PLoS One; 2014; 9(1):e86692. PubMed ID: 24475168
[TBL] [Abstract][Full Text] [Related]
8. Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
Barberio B; Black CJ; Savarino EV; Ford AC
J Crohns Colitis; 2021 May; 15(5):733-741. PubMed ID: 33175102
[TBL] [Abstract][Full Text] [Related]
9. Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis.
Wu D; Yang Z; Zhao C; Yao L
Medicine (Baltimore); 2018 Oct; 97(41):e12657. PubMed ID: 30313056
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis.
Jia X; Guo R; Hu Z; Liu J; Liu J; Li B; Yang Q; He J
Medicine (Baltimore); 2020 Oct; 99(44):e22894. PubMed ID: 33126341
[TBL] [Abstract][Full Text] [Related]
11. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.
Mei WQ; Hu HZ; Liu Y; Li ZC; Wang WG
World J Gastroenterol; 2015 May; 21(19):6044-51. PubMed ID: 26019471
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
[TBL] [Abstract][Full Text] [Related]
13. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
[TBL] [Abstract][Full Text] [Related]
15. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
16. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
17. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
Chande N; McDonald JW; Macdonald JK
Cochrane Database Syst Rev; 2008 Apr; (2):CD006774. PubMed ID: 18425969
[TBL] [Abstract][Full Text] [Related]
18. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
[TBL] [Abstract][Full Text] [Related]
19. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
[TBL] [Abstract][Full Text] [Related]
20. Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study.
Nasuno M; Miyakawa M; Tanaka H; Motoya S
Digestion; 2017; 95(1):67-71. PubMed ID: 28052276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
